Generic placeholder image

Reviews on Recent Clinical Trials

Author(s): Nazarii Kobyliak*, Ludovico Abenavoli, Tetyana Falalyeyeva, Oleksandr Kovalchuk, Dmytro Kyriienko and Iuliia Komisarenko

DOI: 10.2174/1574887115666200709141131

DownloadDownload PDF Flyer Cite As
Metabolic Benefits of Probiotic Combination with Absorbent Smectite in type 2 Diabetes Patients a Randomised Controlled Trial

Page: [109 - 119] Pages: 11

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Numerous non-drug therapies have emerged in recent years for the prevention and improvement of type 2 diabetes (T2D). However, therapies based on dietary modification and/or microbiota may replace a large part of drug therapies in the coming years.

Aim: The aim of the current study was to conduct placebo-controlled randomize clinical trial for the efficiency of a combination of multiprobiotics with smectite absorbent gel (Symbiter-Forte formulation) as an adjunction to the standard anti-diabetic therapy.

Methods: A total of 55 patients met the criteria and were included in double-blind single center RCT, to receive “Symbiter-Smectite” or placebo for 8-weeks administered as a sachet formulation. The primary outcome was the change in HOMA2-IR and insulin sensitivity (% S). Secondary outcomes were glycemic control parameters, β-cells functional activity, anthropometric parameters and markers of a chronic systemic inflammatory response.

Results: Combined use of the probiotic mixture with smectite leads to a significant reduction in HOMA2-IR (3.14±0.97 vs 2.79±0.85; р=0.009) and improvement in % S (34.65±9.92 vs 39.42±12.78; p=0.011) after 8 weeks of the treatment period. Simultaneously, in the secondary outcome analysis lowering of HbA1c, waist circumference but not BMI and pro-inflammatory cytokines IL-1β (p=0.004), TNF-α (p=0.008), IL-6 (p=0.005) and IL-8 (p=0.042) were detected. In placebo group, changes were insignificant.

Conclusion: Probiotic with smectite due to its absorbent activity and stabilization mucus layer properties can impact the synergistic enhancement of a single effect, which manifested with a significant reduction in IR, waist circumference, markers of chronic systemic inflammation and improvement of glycemic profile as compared to placebo.

Keywords: Probiotics, smectite, absorbent, insulin resistance, obesity, type 2 diabetes.

Graphical Abstract

[1]
Mechanick JI. Global dimensions of diabetes: Information and synthesis. Ann Glob Health 2015; 81(6): 733-4.
[http://dx.doi.org/10.1016/j.aogh.2015.12.015] [PMID: 27108140]
[2]
IDF Diabetes Atlas nd https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/19-atlas-6th-edition.html
[3]
Kyriachenko Y, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes 2019; 10(3): 154-68.
[http://dx.doi.org/10.4239/wjd.v10.i3.154] [PMID: 30891151]
[4]
Braga T, Kraemer-Aguiar LG, Docherty NG, Le Roux CW. Treating prediabetes: Why and how should we do it? Minerva Med 2019; 110(1): 52-61.
[http://dx.doi.org/10.23736/S0026-4806.18.05897-4] [PMID: 30371047]
[5]
Almeda-Valdes P, Aguilar-Olivos N, Uribe M, Méndez-Sánchez N. Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9(3): 148-58.
[http://dx.doi.org/10.2174/1574887109666141216103908] [PMID: 25514910]
[6]
Brunton S. Pathophysiology of Type 2 Diabetes: The evolution of our understanding. J Fam Pract 2016; 65(4)(Suppl.): 65.
[PMID: 27262256]
[7]
Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician 2009; 79(1): 29-36.
[PMID: 19145963]
[8]
Sanchez-Rangel E, Inzucchi SE. Metformin: Clinical use in type 2 diabetes. Diabetologia 2017; 60(9): 1586-93.
[http://dx.doi.org/10.1007/s00125-017-4336-x] [PMID: 28770321]
[9]
Leporini C, Russo E, D Angelo S, et al. Insulin-Sensiting effects of tumor necrosis factor alpha inhibitors in rheumatoid arthritis: A systematic review and meta-analysis. Rev Recent Clin Trials 2018; 13(3): 184-91.
[http://dx.doi.org/10.2174/1574887113666180314100340] [PMID: 29542420]
[10]
Ceriello A, deValk HW, Guerci B, et al. The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives. Diabetes Res Clin Pract 2020; 161108053
[http://dx.doi.org/10.1016/j.diabres.2020.108053] [PMID: 32035117]
[11]
Khanna S. Microbiota replacement therapies: Innovation in gastrointestinal care. Clin Pharmacol Ther 2018; 103(1): 102-11.
[http://dx.doi.org/10.1002/cpt.923] [PMID: 29071710]
[12]
Abenavoli L, Scarpellini E, Colica C, et al. Gut microbiota and obesity: A role for probiotics. Nutrients 2019; 11(11)E2690
[http://dx.doi.org/10.3390/nu11112690] [PMID: 31703257]
[13]
Leustean AM, Ciocoiu M, Sava A, et al. Implications of the intestinal microbiota in diagnosing the progression of diabetes and the presence of cardiovascular complications. J Diabetes Res 2018; 20185205126
[http://dx.doi.org/10.1155/2018/5205126] [PMID: 30539026]
[14]
Abenavoli L, Peta V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9(3): 134-40.
[http://dx.doi.org/10.2174/1574887109666141216102458] [PMID: 25514909]
[15]
Kobyliak N, Falalyeyeva T, Bodnar P, Beregova T. Probiotics Supplemented with Omega-3 fatty acids are more effective for hepatic steatosis reduction in an animal model of obesity. Probiotics Antimicrob Proteins 2017; 9(2): 123-30.
[http://dx.doi.org/10.1007/s12602-016-9230-1] [PMID: 27660157]
[16]
Kobyliak N, Falalyeyeva T, Beregova T, Spivak M. Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition. Endokrynol Pol 2017; 68(6): 659-67.
[http://dx.doi.org/10.5603/EP.a2017.0055] [PMID: 29022648]
[17]
Kobyliak N, Falalyeyeva T, Boyko N, Tsyryuk O, Beregova T, Ostapchenko L. Probiotics and nutraceuticals as a new frontier in obesity prevention and management. Diabetes Res Clin Pract 2018; 141: 190-9.
[http://dx.doi.org/10.1016/j.diabres.2018.05.005] [PMID: 29772287]
[18]
Miraghajani M, Dehsoukhteh SS, Rafie N, Hamedani SG, Sabihi S, Ghiasvand R. Potential mechanisms linking probiotics to diabetes: a narrative review of the literature. Sao Paulo Med J 2017; 135(2): 169-78.
[http://dx.doi.org/10.1590/1516-3180.2016.0311271216] [PMID: 28538869]
[19]
Brouillard MY, Rateau JG. [Adsorption potency of 2 clays, smectite and kaolin on bacterial enterotoxins. In vitro study in cell culture and in the intestine of newborn mice Gastroenterol Clin Biol 1989; 13(1): 18-24.
[PMID: 2647564]
[20]
Weese JS, Cote NM, deGannes RVG. Evaluation of in vitro properties of di-tri-octahedral smectite on clostridial toxins and growth. Equine Vet J 2003; 35(7): 638-41.
[http://dx.doi.org/10.2746/042516403775696384] [PMID: 14649353]
[21]
Müller J, Dobler D, Schmidts T, Rusch V. Smectite for medical use and their toxin binding capacity. Journal of food. J Food Nutr Popul Health 2019; 3: 1-5.
[22]
Dupont C, Vernisse B. Anti-diarrheal effects of diosmectite in the treatment of acute diarrhea in children: A review. Paediatr Drugs 2009; 11(2): 89-99.
[http://dx.doi.org/10.2165/00148581-200911020-00001] [PMID: 19301931]
[23]
Roca-Saavedra P, Mendez-Vilabrille V, Miranda JM, et al. Food additives, contaminants and other minor components: Effects on human gut microbiota-a review. J Physiol Biochem 2018; 74(1): 69-83.
[http://dx.doi.org/10.1007/s13105-017-0564-2] [PMID: 28488210]
[24]
Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. Probiotics and smectite absorbent gel formulation reduce liver stiffness, transaminase and cytokine levels in NAFLD associated with type 2 diabetes: A randomized clinical study. Clinical Diabetology 2019; 8: 205-14.
[http://dx.doi.org/10.5603/DK.2019.0016]
[25]
Kobyliak N, Abenavoli L, Falalyeyeva T, Beregova T. Efficacy of probiotics and smectite in rats with non-alcoholic fatty liver disease. Ann Hepatol 2018; 17(1): 153-61.
[http://dx.doi.org/10.5604/01.3001.0010.7547] [PMID: 29311399]
[26]
American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetesd2019. Diabetes Care 2019; 42(Suppl. 1): S13-28.
[http://dx.doi.org/10.2337/dc19-S002] [PMID: 30559228]
[27]
Dolatkhah N, Hajifaraji M, Abbasalizadeh F, Aghamohammadzadeh N, Mehrabi Y, Abbasi MM. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. J Health Popul Nutr 2015; 33: 25.
[http://dx.doi.org/10.1186/s41043-015-0034-9] [PMID: 26825666]
[28]
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-9.
[http://dx.doi.org/10.1007/BF00280883] [PMID: 3899825]
[29]
Montandon SA, Jornayvaz FR. Effects of antidiabetic drugs on gut microbiota composition. Genes (Basel) 2017; 8(10)E250
[http://dx.doi.org/10.3390/genes8100250] [PMID: 28973971]
[30]
Kobyliak N, Falalyeyeva T, Mykhalchyshyn G, Kyriienko D, Komissarenko I. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial. Diabetes Metab Syndr 2018; 12(5): 617-24.
[http://dx.doi.org/10.1016/j.dsx.2018.04.015] [PMID: 29661605]
[31]
Brun JF, Raynaud E, Mercier J. Homeostasis model assessment and related simplified evaluations of insulin sensitivity from fasting insulin and glucose. Diabetes Care 2000; 23(7): 1037-8.
[http://dx.doi.org/10.2337/diacare.23.7.1037] [PMID: 10895873]
[32]
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27(6): 1487-95.
[http://dx.doi.org/10.2337/diacare.27.6.1487] [PMID: 15161807]
[33]
Tonucci LB, Olbrich Dos Santos KM, Licursi de Oliveira L, Rocha Ribeiro SM, Duarte Martino HS. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin Nutr 2017; 36(1): 85-92.
[http://dx.doi.org/10.1016/j.clnu.2015.11.011] [PMID: 26732026]
[34]
Mobini R, Tremaroli V, Ståhlman M, et al. Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab 2017; 19(4): 579-89.
[http://dx.doi.org/10.1111/dom.12861] [PMID: 28009106]
[35]
Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak MY. Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. Eur J Nutr 2017; 56(4): 1535-50.
[http://dx.doi.org/10.1007/s00394-016-1199-8] [PMID: 26988693]
[36]
Li G, Yin J, Gao J, et al. Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes. Arthritis Res Ther 2013; 15(6): 223.
[http://dx.doi.org/10.1186/ar4405] [PMID: 24321104]
[37]
Ruan Y, Sun J, He J, Chen F, Chen R, Chen H. Effect of probiotics on glycemic control: A systematic review and meta-analysis of randomized, controlled trials. PLoS One 2015; 10(7)e0132121
[http://dx.doi.org/10.1371/journal.pone.0132121] [PMID: 26161741]
[38]
Kasińska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a meta-analysis. Pol Arch Med Wewn 2015; 125(11): 803-13.
[http://dx.doi.org/10.20452/pamw.3156] [PMID: 26431318]
[39]
Tiderencel KA, Hutcheon DA, Ziegler J. Probiotics for the treatment of type 2 diabetes: A review of randomized controlled trials. Diabetes Metab Res Rev 2020; 36(1)e3213
[http://dx.doi.org/10.1002/dmrr.3213] [PMID: 31465625]
[40]
Tao YW, Gu YL, Mao XQ, Zhang L, Pei YF. Effects of probiotics on type II diabetes mellitus: a meta-analysis. J Transl Med 2020; 18(1): 30.
[http://dx.doi.org/10.1186/s12967-020-02213-2] [PMID: 31952517]
[41]
González R, de Medina FS, Martínez-Augustin O, et al. Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat. Br J Pharmacol 2004; 141(6): 951-60.
[http://dx.doi.org/10.1038/sj.bjp.0705710] [PMID: 14993105]
[42]
Mahraoui L, Heyman M, Plique O, Droy-Lefaix MT, Desjeux JF. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-α. Gut 1997; 40(3): 339-43.
[http://dx.doi.org/10.1136/gut.40.3.339] [PMID: 9135522]